Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.

导出原文传递

翻译打印收藏纠错

作者： Prados MD ^[1] ; Wara WM ^[2] ; Sneed PK ; McDermott M ; Chang SM ; Rabbitt J ; Page M ; Malec M ; Davis RL ; Gutin PH ; Lamborn K ; Wilson CB ; Phillips TL ; Larson DA

作者单位： Department of Neurosurgery, University of California San Francisco, San Francisco, CA 94143-0372, USA. pradosm ^[1] olimi.it ^[2]

关键词 Antineoplastic Agents Brain Neoplasms Eflornithine Glioblastoma Radiation-Sensitizing Agents 抗肿瘤药脑肿瘤依氟鸟氨酸胶质母细胞瘤辐射增敏药

发布时间 2013-11-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览4

International Journal of Radiation Oncology, Biology, Physics

2001年49卷1期

71-77页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.

International Journal of Radiation Oncology, Biology, Physics

相似文献

International Journal of Radiation Oncology, Biology, Physics

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.

International Journal of Radiation Oncology, Biology, Physics

相似文献

International Journal of Radiation Oncology, Biology, Physics

相关期刊

检索历史清除